Australia's most trusted
source of pharma news
Friday, 25 October 2024
Posted 9 July 2024 AM
GSK has gone all-in on mRNA vaccines for influenza and COVID-19, taking full control of its collaboration with German biotech CureVac.
The two companies began collaborating on mRNA in 2020, and signed a deal on Covid in particular in 2021, which included a 75 million euro (AU$120 million) upfront payment, with the vaccines targeted for availability in 2022.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.